Consolidated Lawsuit Challenges GLP Makers On Adverse Events, Marketing

As CMS takes a bold step by proposing Medicare and Medicaid cover GLP-1s to treat obesity as a chronic disease, over a thousand patients are simultaneously asking the courts to force GLP-1 makers to update their labels to warn of dangerous adverse events and arguing the drug makers pushed the argument that obesity is a disease and that their drugs are the proper treatment through inappropriate marketing. The first major filing has been submitted in a multi-district consolidated proceeding involving...